https://orcid.org/0000-0002-2962-8737
References
- Nigwekar SU, Thadhani R, Brandenburg VM, Ingelfinger JR. Calciphylaxis. N Engl J Med. 2018;378(18):1704–1714. doi:10.1056/NEJMra1505292
- Seethapathy H, Noureddine L. Calciphylaxis: approach to diagnosis and management. Adv Chron Kidney Dis. 2019;26(6):484–490. doi:10.1053/j.ackd.2019.09.005
- Dobry AS, Ko LN, St John J, Sloan JM, Nigwekar S, Kroshinsky D. Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: a case-control study. JAMA Dermatol. 2018;154(2):182–187. doi:10.1001/jamadermatol.2017.4920
- Bahrani E, Perkins IU, North JP. Diagnosing calciphylaxis: a review with emphasis on histopathology. Am J Dermatopathol. 2020;42(7):471–480. doi:10.1097/DAD.0000000000001526
- Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD: a systematic review and metaanalysis. Kidney Int Rep. 2019;4(2):231–244. doi:10.1016/j.ekir.2018.10.002
- Panchal S, Holtermann K, Trivedi N, Regunath H, Yerram P. Calciphylaxis: an analysis of concomitant factors, treatment effectiveness and prognosis in 30 patients. Int J Nephrol Renovasc Dis. 2020;13:65–71. doi:10.2147/IJNRD.S241422
- Galloway PA, El-Damanawi R, Bardsley V, et al. Vitamin K antagonists predispose to calciphylaxis in patient with end-stage renal disease. Nephron. 2015;129(3):197–201. doi:10.1159/000371449
- Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27:1580–1584. doi:10.1093/ndt/gfr658
- Medicines and Healthcare Products Regulatory Agency. Calciphylaxis is a very rare but serious condition causing vascular calcification and skin necrosis. Drug Safety Update; 2016.
- Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153(3):309–314. doi:10.1001/jamadermatol.2016.4821
- Ackermann F, Levy A, Daugas E, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol. 2007;143(10):1336–1337. doi:10.1001/archderm.143.10.1336
- Vassa N, Twardowski ZJ, Campbell J. Hyperbaric oxygen therapy in calciphylaxis‐induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis. 1994;23(6):878–881. doi:10.1016/S0272-6386(12)80145-4
- Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol. 2015;10(5):800–807. doi:10.2215/CJN.10221014
- Garza-MayersAC, ShahR, SykesDB, NigwekarSU, KroshinskyD. The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis. Am J Nephrol. 2018;48(3):168–171. Doi:10.1159/000491881